Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: A prospective study

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1955-1963

  Kornblau, Steven M ^a,b   Andreeff, Michael ^a   Hu, Shi Xue ^a   Xu, Hong Ji ^a   Patel, Shilpen ^a   Theriault, Alexandra ^a   Koller, Charles ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a   Deisseroth, Albert B ^a,c   Benedict, William F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; RETINOBLASTOMA PROTEIN;

EID: 0031821803     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Shivdasani, R. A., and Orkin, S. H. The transcriptional control of hematopoiesis. Blood, 87: 4025-4039, 1996.
2. Bandara, L. R., Adamczewki, J. P., Hunt, T., and La Thangue, N. B. Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature (Lond.). 352: 249-251, 1991.
3. Peter, M., Nakagawa, J., Doree, M., Labbe, J. C., and Nigg, E. A. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell, 60: 791-801, 1990.
4. Lin, B. T. Y., Gruenwald, S., Morla, A. O., Lee, W. H., and Wang, J. Y. J. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J., 10: 857-864, 1991.
5. del Giglio, A., Drach, J., Kornblau, S. M., Patel, S., Novaes, M., Khetan, R., Sawaya, N., Dorlhiac-Llacer, P., Chamone, D. F., Andreeff, M., Hester, J., and Deisseroth, A. D. Quantitative expression of proliferating cell nuclear antigen by Western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk. Lymphoma, 19: 235-241, 1995.
6. Ewen, M., Sluss, H., Sherr, C., Matsushime, H., Kato, J., and Livingston, D. Functional interactions of the retinoblastoma protein with mammalian d-type cyclins. Cell, 73: 487-497, 1993.
7. Dowdy, S., Hinds, P., Louie, K., Reed, S., Arnold, A., and Weinberg, R. Physical interaction of the retinoblastoma protein with human D cyclins. Cell, 73: 499-511, 1993.
8. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
9. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
10. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. Waf1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
11. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
12. Xlong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinase. Nature (Lond.), 366: 701-704, 1996.
13. Chellappan, S. P., Hiebert, S., Mudryi, M., Horowitz, J. M., and Nevins, J. R. The E2F transcription factor is a cellular target for the RB protein. Cell, 65: 1053-1061, 1991.
14. Bagchi, S., Weinmann, R., and Raychaudhuri, P. The retinoblastoma protein copurifies with E2F-1 and an E1A-regulated inhibitor of the transcription factor E2F. Cell, 65: 1063-1072, 1991.
15. Shirodkar, S., Ewen, M., DeCaprio, J. A., Morgan, J., Livingston, M., and Chittenden, T. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell, 68: 157-166, 1992.
16. Cao, L., Faha, B., Dembski, M., Tsai, L. H., Harlow, E., and Dyson, N. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature (Lond.), 355: 176-179, 1992.
17. Hiebert, S. W., Chellappan, S. P., Horowitz, J. M., and Nevins, J. R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev., 6: 177-185, 1992.
18. La Thangue, N. B. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci., 19: 108-114, 1994.
19. 1 phase of the cell cycle. Cell. 67: 293-302, 1991.
20. Kornblau, S. M., Xu, H-J., Zhang, W., Hu, S-X., Beran, M., Smith, T. L., Hester, J., Estey, E., Benedict, W., and Deisseroth, A. B. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 84: 256-261, 1994.
21. Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., Claxton, D., and Deisseroth, A. D. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1: 1051-1057, 1995.
22. Zhang, W., Xu, H-J., Kornblau, S. M., Drach, J., Hu, S-X., Andreeff, M., Benedict, W. F., and Deisseroth, A. B. Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. Leuk. Lymphoma, 16: 191-198, 1995.
23. Tang, J. L., Yeh, S. H., Chen, P. J., Lin, M. T., Tien, H. F., and Chen, Y. C. Inactivation of the retinoblastoma gene in acute myelogenous leukaemia. Br. J. Haematol., 82: 502-507, 1992.
24. Campos, L., Rouault, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P., and Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81: 3091-3096, 1993.
25. Kornblau, S. M., Xu, H. J., del Giglio, A., Hu, S. X., Zhang, W., Calvert, L., Beran, M., Estey, E., Andreeff, M., Trujillo, J., Cork, M. A., Smith, T. L., Benedict, W. F., and Deisseroth, A. B. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res., 52: 4587-4590, 1992.
26. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., Kornblau, S., Pierce, S., Freireich, E. J., Deisseroth, A., and Keating, M. Use of G-CSF before during and after fludarabine + ara-C induction therapy in newly diagnosed AML or MDS: comparison with fludarabine + ara-C without G-CSF. J. Clin. Oncol., 12: 671-678, 1994.
27. Estey, E., Andreeff, M., O'Brien, S., and Kantarjian, H. Treatment of newly diagnosed acute promyelocytic leukemia (APL) without 1-β-D-arabinofuranosylcytosine (ara-C). Blood, 10: 266a, 1996.
28. Paggi, M. G., de Fabritiis, P., Bonetto, F., Amadio, L., Santarelli, G., Spadea, A., Gentile, F. P., Floridi, A., and Felsani, A. The retinoblastoma gene product in acute myeloid leukemia: a possible involvement in promyelocytic leukemia. Cancer Res., 55: 4552-4556, 1995.
29. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
30. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. J. R. Stat. Soc., 50: 163-170, 1966.
31. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
32. Schiffer, C. A., Lee, E., Tomiyasu, T., Wiernik, P., and Testa, J. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood, 73: 263-270, 1989.
33. Estey, E., Smith, T. L., Keating, M. J., McCredie, K. B., Gehan, E. A., and Freireich, E. J. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia (Baltimore), 3: 257-263, 1989.
34. Keating, M. J., Cork, A., Broach, Y., Smith, T., Walters, R. S., McCredie, K. B., Trujillo, J., and Freireich, E. J. Toward a clinically relevant cytogenetic classification of AML. Leuk. Res., 11: 119-133, 1987.
35. Estey, E., Smith, T. L., Keating, M., McCredie, K., Freireich, E. J., and Gehan, E. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia (Baltimore), 3: 257-263, 1989.
36. 1 cells: correlation to changes in total RB protein level. Oncogene, 6: 1139-1146, 1991.
37. 1 is dependent on growth status. Oncogene, 6: 317-322, 1991.
38. Snedecor, G. W., and Cochran, W. G. Statistical Methods, p. 116. Ames, Iowa: Iowa State University Press, 1980.
39. Chen, P. L., Scully, P., Shew, J. Y., Wang, J., and Lee, W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198, 1989.
40. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C. M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58: 1085-1095, 1989.
41. Jamal, R., Gale, R. E., Thomas, N. S. B., Wheatley, K., and Linch, D. C. Reduced or abnormal expression of pRB in AML blasts is not a major prognostic factor. Br. J. Haematol., 93: 67, 1996.
42. Sauerbrey, A., Stammler, G., Zintl, P., and Volm, M. Expression and prognostic value of the retinoblastoma tumour suppressor gene (RB-1) in childhood acute lymphoblastic leukemia. Br. J. Haematol., 94: 99-104, 1996.
43. Cote, R., Dunn, M. D., Chatterjee, S. J., Stein, J. P., Shi, S-R., Tran, Q-C., Hu, S-X., Xu, H-J., Groshen, S., Taylor, C. R., Skinner, D. G., and Benedict, W. F. Elevated and absent pRb expression is associated with bladder cancer progression, and has cooperative effects with p53. Cancer Res., 58: 1090-1094, 1998.
44. Grossman, H. B., Liebert, M., Antelo, M., Dinney, C. P. N., Hu, S-X., Palmer, L., and Benedict, W. F. p53 and RB expression predict progression in T1 bladder cancer. Clin. Cancer Res., 4: 829-834, 1998.
45. Benedict, W. F., Lerner, S. P., Zhou, J., Shen, X., Tokanaga, H., and Czerniak, B. Level of retinoblastoma protein expression correlates with p16(CDKN2/MTS-1/INK4A) status in bladder cancer. Oncogene, in press, 1998.